Medscheme released updated MEDICINE EXCLUSION LIST APRIL 2023

By Staff Writer

April 10, 2023

Some items listed as REQUIRING PRE-AUTHORISATION:

  • Forxiga (Dapagliflozin)
  • Byetta (Exenatide)
  • Janumet (Metformin/Sitagliptin)
  • Onglyza (Saxagliptin)
  • Januvia (Sitagliptin)
  • Galvus (Vildagliptin) + including Metformin combinations
  • Liptruzet (Atorvastatin/Ezetimibe)
  • Ezetrol (Ezetimibe)
  • Inegy(Ezetimibe/Simvastatin)

Details regarding the EXCLUDED ITEMS:

  • Trulicity (Dulaglutide)
  • Jardiance (Empagliflozin)
  • Xultophy (Insulin Degludec and Liraglutide)
  • Soliqua (Insulin Glargine and Lixisenatide)
  • Victoza (Liraglutide)
  • Synjardy (Metformin and Empagliflozin)
  • Ozempic (Semaglutide)
Reference url

Recent Posts

Evolving Strategies in Type 2 Diabetes Management: NICE Guideline Update 2025

By Staff Writer

August 21, 2025

Type 2 diabetes management in adults is undergoing significant changes with the draft 2025 NICE guideline update. What are the main improvements in medication, monitoring, and patient care for adults with type 2 diabetes? The answer: The new NICE recommendations prioritize a broader use of SGL...
Unlocking Self-Care South Africa: Strategies and Challenges in Healthcare Reform

By João L. Carapinha

August 18, 2025

The recent interview with Nicola Brink, CEO of the Self-Care Association of South Africa, published by Executive Forecast, highlights both the systemic challenges and transformative opportunities within the country’s self-care South Africa sector. The article details persistent regulatory delays—...
Urgent Care Effectiveness: Exploring Canadian Centre Models and Health System Impacts

By João L. Carapinha

August 12, 2025

Urgent care effectiveness has become a central question for Canada’s health systems as policymakers look for tangible ways to relieve emergency department (ED) overcrowding and improve timely access to care. Many people want to know: Do urgent care centres actually help reduce pressure on hospita...